Skip to content
Screener

BioMarin Pharmaceuticals BMRN VOXZOGO — Total revenues

Other product segments

VIMIZIM
$194.37M-9.8%
NAGLAZYME
$135.26M+5.0%
PALYNZIQ
$135.17M+27.6%
GALAFOLD
$105.75M—
BRINEURA
$51.37M+5.5%
ALDURAZYME
$43.54M-22.9%
POMBILITI + OPFOLDA
$30.26M—
KUVAN
$24.44M-9.6%
ROCTAVIAN
$11.71M+27.3%
Royalty and other revenues
$5.32M-57.2%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
VOXZOGO$252,528$221,391$472,408$435,145
Metabolic Conditions (formerly Enzyme Therapies):
VIMIZIM194,371215,424404,575403,770
NAGLAZYME135,255128,867265,329243,157
PALYNZIQ135,167105,938224,725199,207
GALAFOLD(1)105,748—105,748—
BRINEURA51,37048,69298,47489,054
ALDURAZYME43,53956,43780,281105,414

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's VOXZOGO — total revenues?
BioMarin Pharmaceuticals (BMRN) reported VOXZOGO — total revenues of $252.53M in Q2 2026.
How has BioMarin Pharmaceuticals's VOXZOGO — total revenues changed year-over-year?
BioMarin Pharmaceuticals's VOXZOGO — total revenues increased by 14.1% year-over-year, from $221.39M to $252.53M.
What is the long-term trend for BioMarin Pharmaceuticals's VOXZOGO — total revenues?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's VOXZOGO — total revenues has grown at a 254.7% compound annual growth rate (CAGR), from $5.86M to $926.92M.
What does VOXZOGO — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific therapeutic product within the company's rare disease portfolio. It captures the aggregate financial inflow from all global markets and distribution channels associated with this particular drug. This figure is a primary indicator of the product's commercial adoption and market penetration within its target patient population.

Ask your AI about BioMarin Pharmaceuticals's voxzogo — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude